Death is imminent," Wright said. Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi.

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Unfortunately, the current drug pricing bill fails to take a holistic ... and Eli Lilly’s Humalog (insulin lispro) by 2024. The organisation plans to offer the biosimilars at a ‘significant ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

This all-encompassing guide investigates the smart insulin pen and its influence on diabetes management. Here's what you need ...

GZR18 is an investigational drug and is not approved for use in any country. Gan & Lee Pharmaceuticals does not endorse the use of any unapproved drug or indication. The Phase 2b clinical trial ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs Humalog and insulin lispro were in short supply. Novo Nordisk ...

Earlier this year, Eli Lilly reported temporary shortages of Humalog and insulin lispro in 10-milliliter ... are approved to treat weight loss. Drug companies have invested hundreds of millions ...